Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
Authors
Hess, G.Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Stilgenbauer, S.
Thieblemont, C.
Lambert, J.
Zilioli, V. R.
Sancho, J. M.
Ubieto, A. J.
Fischer, L.
Eyre, T. A.
Keeping, S.
Park, J. E.
Wu, J. J.
Siddiqi, R.
Reitan, J.
Wade, S.
Salles, G.
Affiliation
Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center, University Medical School of the Johannes Gutenberg-University, Mainz, GermanyIssue Date
2022
Metadata
Show full item recordAbstract
Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6-20.0) in the overall cohort, 5.5 months (95% CI 3.9-8.2) in 91 patients without post-BTKi therapy, and 23.8 months (95% CI 18.9-30.1) in 149 patients who received post-BTKi therapy (excluding chimeric antigen receptor T-cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post-BTKi therapy, with lenalidomide-containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post-BTKi therapy was 9.7 months (95% CI 6.3-12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.Citation
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. British journal of haematology. 2022 Oct 18. PubMed PMID: 36257914. Epub 2022/10/19. eng.Journal
British Journal of HaematologyDOI
10.1111/bjh.18519PubMed ID
36257914Additional Links
https://dx.doi.org/10.1111/bjh.18519Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.18519
Scopus Count
Collections
Related articles
- Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
- Authors: Burkart M, Karmali R
- Issue date: 2022 Mar 1
- Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance.
- Authors: Liu S, Yang P, Wang L, Li C, Zhang W, Wang J, Jing H
- Issue date: 2022 Oct
- Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
- Authors: Petersohn S, Salles G, Wang M, Wu J, Wade SW, Simons CL, Bennison C, Siddiqi R, Peng W, Kloos I, Castaigne G, Hess G
- Issue date: 2022 Jan-Dec
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
- Authors: Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
- Issue date: 2023 Jan 20
- MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress).
- Authors: Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, Jurczak W, Wang Y, Cheah CY, Gandhi M, Chay C, Sharman J, Andorsky DJ, Song Y, Stark A, Muthig V, Wang ML
- Issue date: 2022 Oct